What НеоЦитотект Treats: Main Uses and Benefits

The main therapeutic use of НеоЦитотект (Cytomegalovirus Immune Globulin Intravenous or CMV-IGIV) is used in situations involving certain distressing symptoms, generally within domains where additional symptomatic support is needed. This therapy is commonly used across conditions presenting with acute episodes, relevant in conditions characterized by periods of heightened symptoms like those linked to cytomegalovirus in the context of solid organ transplantation, including the kidney, lung, liver, pancreas, and heart.

---

CMV infection in these contexts presents with systemic or localized discomfort and is relevant when supportive symptom management is appropriate. The therapy helps address symptom clusters related to inflammatory or irritative states often linked to CMV. The therapy is considered relevant when supportive symptom management is appropriate during temporary physiological imbalance.

---

By providing supportive relief, the product contributes to easing the overall symptom burden and may assist with managing acute or disruptive symptom patterns linked to CMV. This use may assist with maintaining functional stability during phases when symptoms become more noticeable for transplant recipients. The treatment is considered relevant when short-term symptomatic assistance is needed and is applied in scenarios where additional management of discomfort is required in these individuals.

“The treatment is commonly used when short-term symptomatic assistance is needed to support the patient during difficult episodes by easing distress.”

Quick Fact: Helps manage Symptoms related to inflammatory or irritative states

Who can and cannot use НеоЦитотект?

НеоЦитотект (a cytomegalovirus human immunoglobulin) is a prescription medicine, and its use is strictly determined by a patient’s clinical status as defined in official regulatory documents.

Contraindications

This medicine is contraindicated (must not be used) in patients with selective IgA deficiency who have developed antibodies to IgA. The presence of these antibodies can lead to severe allergic or anaphylactic reactions when the patient is exposed to IgA, which is present in trace amounts in the product.

Eligibility Restrictions and Special Considerations

Use requires special caution and is restricted in several populations due to the risk of thromboembolic events (blood clots) and acute kidney injury. The infusion should be administered at the minimum dose and rate practicable for patients with:

• Pre-existing risk factors for thrombosis, including advanced age, obesity, high blood pressure (hypertension), diabetes mellitus, a history of vascular disease, or known clotting disorders.
• Risk factors for kidney dysfunction, including pre-existing kidney problems, diabetes, volume depletion, and those taking other medicines that affect the kidneys.
• Patients with an untreated infection or underlying chronic inflammation may also experience adverse reactions more frequently and require close monitoring during infusion.

The official interaction profile for НеоЦитотект (Human Cytomegalovirus Immunoglobulin) is strictly based on its properties as a plasma-derived biological medicine. Regulatory documentation confirms the product does not have documented pharmacokinetic interactions involving the cytochrome P450 enzyme system or major drug transporters. Therefore, interactions requiring dose modification based on metabolic or transporter pathways are not specified in official labeling.

The primary and most significant interaction documented in prescribing information is pharmacodynamic interference with certain vaccines.

Documented Interaction

Interacting Substance Category	Interaction Type	Regulatory Constraint
Live Attenuated Virus Vaccines (e.g., Measles, Mumps, Rubella, Varicella)	Pharmacodynamic interference	Mandatory Deferral of vaccination

The antibodies present in НеоЦитотект may officially interfere with the immune response to these vaccines, potentially resulting in reduced vaccine efficacy. This requires that vaccination with a live attenuated virus vaccine must be deferred for a period of approximately three months following the administration of the immunoglobulin. Observing this separation interval is a formal regulatory requirement to ensure the vaccine can elicit a proper immune response. No interactions are officially documented with food, alcohol, or herbal products.

The mechanism of action for НеоЦитотект centers on passive immunization, involving the administration of pre-formed Immunoglobulin G (IgG) antibodies. The primary mechanistic event is the neutralization of Cytomegalovirus (CMV). The medication supplies high concentrations of IgG antibodies that specifically recognize and bind to antigens on the CMV surface. This binding action coats the virus, mechanically blocking its ability to attach to and enter host cells. This immediate interference with the virus's infectivity initiates the subsequent molecular cascade.

Once the antibodies bind to the CMV particles, they form immune complexes. This step engages specific pathways within the host's innate immune system, such as opsonization and the complement cascade. These mechanisms act to effectively mark the clustered viral particles for rapid removal by phagocytic cells. This process modulates the influence of excessive viral activity and decreases the quantity of circulating infectious viral particles.

How to Use НеоЦитотект

НеоЦитотект (Human Cytomegalovirus Immunoglobulin) is administered exclusively via intravenous (IV) infusion under professional supervision, following a defined protocol for prophylaxis in organ transplant recipients. This specialized biological product must not be administered by any other route, such as intramuscular (IM) or subcutaneous injection.

The medicine is used as a fixed, time-bound course spanning 16 weeks post-transplant. The first infusion must be given within 72 hours of the transplant procedure, with subsequent doses following a bi-weekly schedule.

The dosage is strictly body-weight dependent (mg/kg) and varies based on the type of organ received. The maximum dose administered during any single infusion is 150 mg of Immunoglobulin per kilogram of body weight. The specific dosing regimen follows a tapering structure over the 16-week period:

Transplant Type	Dose at 0–72 Hours Post-transplant	Doses at Weeks 2, 4, 6, 8	Doses at Weeks 12, 16
Kidney	150 mg/kg	100 mg/kg	50 mg/kg
Liver, Heart, Lung, Pancreas	150 mg/kg	150 mg/kg	100 mg/kg

Administration requires a constant infusion pump and an in-line filter. The infusion rate is carefully controlled, starting at a low speed and gradually increasing, with a maximum rate that must not be exceeded, such as 60 mg/kg/hr. The mg/kg dosing structure applies uniformly across adult and pediatric patients.

Research Evidence / Overview of Studies for НеоЦитотект

This overview summarizes the available research concerning НеоЦитотект (Human Cytomegalovirus Immunoglobulin Intravenous, or CMV-IGIV). The information focuses exclusively on the design of the studies and the patterns observed in research, without offering any medical advice, clinical interpretation, or details on how the medicine works.

---

Evidence for Preventing Cytomegalovirus (CMV) Disease in Organ Transplant Recipients

Studies investigated the role of this hyperimmune globulin in research contexts assessing outcomes related to the prophylaxis (prevention) of Cytomegalovirus (CMV) disease following solid organ transplantation. Researchers have used Randomized Controlled Trials (RCTs) to compare the immunoglobulin against an inactive substance (placebo) or against standard preventative care. The studies monitored outcomes related to the incidence of CMV infection (measuring the presence of the virus in the blood) and the occurrence of specific CMV disease in various organs. Findings describe patterns observed in the studies regarding the frequency of infection in the observed patient populations.

A key limitation is that much of the core randomized evidence was conducted before the routine use of highly effective antiviral medications. This means that the results apply only to the populations studied under those specific conditions. Evidence contributes to understanding symptom patterns, but the studies often have modest sample sizes and focus on a narrow scope of outcomes.

---

Comparative Studies and Use alongside Antivirals

Studies have explored the use of НеоЦитотект in research settings where it was administered alongside standard preventative treatment, particularly antiviral agents. This research was conducted to observe what differences were measured in outcomes when the immunoglobulin was administered compared to using the antiviral agent alone. Findings were mixed across different study designs, patient populations, and organ types, leading to heterogeneous data regarding the observed measurements of infection and disease incidence.

The use of this medicine in the context of current preventative care (antiviral drugs) means that certainty remains low regarding the additional measurements observed when the immunoglobulin is included. Comparative evidence is lacking for many current treatment scenarios, and subgroup findings are uncertain.

---

What is Still Uncertain about the Research Base

One significant gap is the narrow focus of the research. Studies predominantly investigate the medicine’s role in prophylaxis. There is a notable absence of large-scale, controlled data examining the use of the medicine for the treatment of established CMV disease. Furthermore, while some studies have collected data on patient and graft survival for up to a year or more, long-term effects are not fully established. Data for certain groups, such as pediatric transplant recipients, remain insufficient.

Key Studies & References

1. Cytomegalovirus Infection - NIH Bookshelf Overview
2. Immune globulin - MedlinePlus Medical Encyclopedia

Common questions about НеоЦитотект (FAQ)

Q: What is НеоЦитотект and how does it work?

НеоЦитотект is an intravenous immunoglobulin (IVIg) product. It is a sterile solution made from human plasma that contains highly purified antibodies, also known as immunoglobulins (IgG). Specifically, it contains a high concentration of antibodies against human cytomegalovirus (HCMV). These antibodies work by providing passive immunity, which means they directly introduce antibodies that can help the body neutralize or fight the CMV virus. This is used in certain high-risk patients to help prevent or treat CMV infection.

---

Q: What is НеоЦитотект used for?

НеоЦитотект is primarily used to prevent serious illness caused by human cytomegalovirus (CMV) infection in individuals who are immunocompromised or at high risk. This often includes:

• Transplant recipients, such as those who have received an organ or bone marrow transplant.
• Newborns (neonates) who are at risk due to maternal CMV infection.

It works to protect these vulnerable patients by giving them a dose of pre-formed antibodies to combat the virus.

---

Q: Who should not receive НеоЦитотект?

НеоЦитотект should not be given to individuals with certain conditions. You must inform your healthcare provider if you have:

• A known, severe, or life-threatening allergic reaction to human immunoglobulins or any other component of the preparation.
• A severe deficiency of the antibody IgA and a known history of developing antibodies against IgA, as this can increase the risk of a serious allergic reaction.

Your doctor will carefully assess your medical history before deciding if this treatment is appropriate for you.

---

Q: What are the common side effects of НеоЦитотект?

Like many medications, НеоЦитотект can cause side effects. The most common and generally mild side effects are often related to the infusion itself, and may include:

• Headache
• Dizziness or light-headedness
• Nausea and/or vomiting
• Chills or fever
• Fatigue
• Back or joint pain

These reactions usually decrease when the infusion rate is slowed down or after treatment is finished. Severe reactions are less common but require immediate medical attention.

---

Q: How is НеоЦитотект administered?

НеоЦитотект is administered as a slow intravenous infusion (a drip into a vein). It must be given by a healthcare professional in a hospital or clinical setting. The specific dosage and the rate at which the infusion is given are determined by your doctor based on your medical condition, weight, and the reason for treatment. It is important that the infusion is given slowly, especially at the beginning, to minimize the risk of side effects.

---

Q: Can НеоЦитотект transmit infectious agents?

Neocytotect is made from human plasma. To minimize the risk of transmitting infectious agents, strict manufacturing processes are used. This includes:

• Selecting plasma donors through rigorous screening.
• Testing plasma for known viruses.
• Applying viral inactivation and removal steps (e.g., pasteurization, solvent/detergent treatment) during the manufacturing process.

While these measures greatly reduce the risk of virus transmission, the possibility of transmitting unknown infectious agents cannot be completely ruled out, as with all plasma-derived products. Your healthcare provider will weigh this small theoretical risk against the benefit of preventing serious CMV disease.

The storage and disposal of NeoCytotect (Human Cytomegalovirus Immunoglobulin) must strictly adhere to the requirements specified in official regulatory labeling.

---

Storage Conditions

Requirement	Specification
Temperature	Store in a refrigerator between 2 C to 8 C (36 F to 46 F).
Freezing/Light	Do not freeze. Store in the original package to protect from light.
Post-Opening Stability	Must be used immediately after first opening the vial.
Child Safety	Keep this medicine out of the sight and reach of children.

---

Disposal Instructions

Disposal of unused medicinal product or waste material must be carried out in accordance with local requirements for pharmaceutical waste. This medicine must not be thrown away via household waste or wastewater.